Core Viewpoint - The dispute between Jiangsu Wuzhong and Aimeike over the exclusive agency rights for the AestheFill product highlights the intense competition in the medical aesthetics industry, particularly regarding the popular "childlike" injection products [1][33]. Group 1: Company Disputes - Jiangsu Wuzhong and Aimeike are involved in a conflict over the exclusive distribution rights of the AestheFill product, with Aimeike's subsidiary REGEN Biotech, Inc. sending a termination notice to Jiangsu Wuzhong's subsidiary, Datou Medical [1][2]. - Datou Medical was granted exclusive agency rights for AestheFill in China until August 28, 2032, but allegations have arisen regarding the transfer of these rights to Jiangsu Wuzhong's controlling shareholder [6][7]. - Jiangsu Wuzhong claims that the termination notice's reasons are factually incorrect and asserts that the exclusive distribution agreement remains legally binding [25][32]. Group 2: Financial Implications - Jiangsu Wuzhong is facing significant financial challenges, including a projected net loss of approximately 60 million to 40 million yuan for the first half of 2025 [26]. - The AestheFill product has been a key driver for Jiangsu Wuzhong's financial recovery, with sales revenue from AestheFill contributing significantly to the company's overall income [28][30]. - Aimeike's revenue from its injection products, including its own childlike injection, has shown growth, indicating that regaining AestheFill's agency rights could further enhance its financial performance [30]. Group 3: Industry Context - The medical aesthetics market is becoming increasingly competitive, with multiple players entering the field, including cosmetic companies and new entrants like JD Health [36][37]. - The dispute reflects broader trends in the industry, where companies are vying for market share in the lucrative childlike injection segment, which has seen a surge in demand [33][36]. - The outcome of this dispute will likely impact the market positions and future prospects of both Jiangsu Wuzhong and Aimeike within the medical aesthetics sector [32][33].